Treasurer of the State of North Carolina
ITCI

Treasurer of the State of North Carolina’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Treasurer of the State of North Carolina’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-47,100
Closed -$6.21M – 1045
2025
Q1 		$6.21M Buy
47,100
+1,840
+4% +$229K 0.02% 529
2024
Q4 		$3.78M Buy
45,260
+290
+0.6% +$23.8K 0.01% 683
2024
Q3 		$3.29M Buy
44,970
+180
+0.4% +$13.5K 0.01% 732
2024
Q2 		$3.07M Buy
+44,790
New +$3.11M 0.01% 734

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.16B AUM 18.64% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Treasurer of the State of North Carolina's ITCI Position: Q2 2025 in Review

Treasurer of the State of North Carolina sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 47,100 shares — an estimated $6.21M sold.

Treasurer of the State of North Carolina first reported a position in ITCI in Q2 2024 and held it in 4 quarters. The position peaked at $6.21M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Treasurer of the State of North Carolina reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Treasurer of the State of North Carolina sold 47,100 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $6.21M.
  • Treasurer of the State of North Carolina first reported a position in Intra-Cellular Therapies Inc. in Q2 2024 and held it in 4 quarters.
  • Treasurer of the State of North Carolina's Intra-Cellular Therapies Inc. position peaked at $6.21M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Treasurer of the State of North Carolina's 13F filing for Q2 2025, filed 14 Aug 2025.